Ontology highlight
ABSTRACT: Background
Spinal cord astrocytoma is a rare neoplasm, and patients usually recur within months after surgery. There is currently a lack of consensus regarding post-operative treatment. Clinical data on the activity of systemic treatment like chemoradiotherapy and anti-angiogenic agents also remained scant. Next-generation sequencing (NGS) -based genomic profiling thus may help identify potential treatment options for a subset of patients that harbor actionable genetic alterations.Case presentation
We reported for the first time a refractory case of grade III spinal cord astrocytoma that underwent two surgeries but eventually progressed following post-operative chemoradiotherapy plus bevacizumab. Hybridization capture-based NGS using a 381-gene panel disclosed cyclin dependent kinase 4 (CDK4) amplification and after receiving a triplet regimen containg palbociclib for 15 months, the patient achieved complete response.Conclusions
This case demonstrated the importance of genetic profiling and the benefit of a multi-modality treatment strategy in cancer management.
SUBMITTER: Lin J
PROVIDER: S-EPMC7346338 | biostudies-literature | 2020 Jul
REPOSITORIES: biostudies-literature
Lin Jietao J Yu Ling L Fu Yuanfeng Y Chen Hanrui H Zheng Xinting X Wang Shutang S Gao Chan C Cao Yang Y Lin Lizhu L
BMC cancer 20200708 1
<h4>Background</h4>Spinal cord astrocytoma is a rare neoplasm, and patients usually recur within months after surgery. There is currently a lack of consensus regarding post-operative treatment. Clinical data on the activity of systemic treatment like chemoradiotherapy and anti-angiogenic agents also remained scant. Next-generation sequencing (NGS) -based genomic profiling thus may help identify potential treatment options for a subset of patients that harbor actionable genetic alterations.<h4>Ca ...[more]